Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.01.008 [0.03%]
北村浩志，塚元大二，柏根善之等. 对于第 2 次经尿道切除术后阴性的高危T1期膀胱癌患者，密切监测是否不劣于卡介苗膀胱内灌注：JCOG1019 非劣效性 III 期临床试验. Eur Urol. 在线发表前. https://doi.org/10.1016/j.eururo.2026.01.008
Roberto Contieri,Massimo Lazzeri,Sisto Perdonà et al.
Roberto Contieri et al.
Reply to Roberto Contieri, Massimo Lazzeri, Sisto Perdonà, and Rodolfo Hurle's Letter to the Editor re: Kitamura, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur [0.03%]
Contieri R, Lazzeri M, Perdonà S, Hurle R发致编辑信的回复：关于Kitamura T, Tsukamoto T, Kakehi Y等.高危T1期膀胱癌的主动监测与卡介苗灌注治疗对比：一项随机、非劣效性III期临床试验（JCOG1019）《欧洲泌尿学会杂志》
Hiroshi Kitamura,Hiroyuki Nishiyama
Hiroshi Kitamura
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer [0.03%]
一项关于转移性前列腺癌患者的系统治疗与联合原发灶根治性局部治疗的疗效比较的II期随机对照试验
Brian F Chapin,Marc Smaldone,Amado J Zurita et al.
Brian F Chapin et al.
Background and objective: Studies reported to date indicate that local therapy may improve outcomes in men with de novo metastatic (M1) prostate cancer (PCa). The aim of this study was to evaluate the effect of local ther...
KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model [0.03%]
Kim-1和循环肿瘤DNA是寡转移性透明细胞肾癌的预后标志物：多变量预后模型的发展
Chad Tang,Aaron Seo,Alexander D Sherry et al.
Chad Tang et al.
Better tools are needed for clinical decision-making in oligometastatic clear-cell renal cell carcinoma (ccRCC). Plasma KIM-1 concentrations and circulating tumor DNA (ctDNA) were measured in a clinical trial evaluating metastasis-directed ...
Re: Soluble MAdCAM-1 as a Biomarker in Metastatic Renal Cell Carcinoma [0.03%]
可溶性MAdCAM-1作为转移性肾细胞癌生物标志物的研究回复信
Yuanan Li,Yifan Liu,Bingnan Lu et al.
Yuanan Li et al.
Re: Maxime Pattou, Elliot Tokarski, Chris Bangma, et al. Introducing the Sustainable Urology Recommendations Score: Weighing Environmental Impact Within Urological Guidelines. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.10.019 [0.03%]
关于马西姆·帕图、埃利奥特·托卡尔斯基、克里斯·邦玛等。介绍可持续泌尿外科推荐评分：在泌尿外科指南中权衡环境影响。Eur Urol。即将出版。https://doi.org/10.1016/j.eururo.2025.10.019
Emilien Seizilles de Mazancourt,Jad Kassir,Kevin Kaulanjan
Emilien Seizilles de Mazancourt
Less Is More? How Much Bacillus Calmette-Guérin (BCG) Is Enough for BCG-naïve High-risk Non-muscle invasive Bladder Cancer? [0.03%]
量力而行？初治高危非肌层浸润性膀胱尿路上皮癌的卡介菌（布氏杆菌）治疗多少剂量为宜？
David J Nusbaum,Roger Li,Charles C Peyton et al.
David J Nusbaum et al.